Biomerica, Inc. announced that the American Medical Association CPT editorial panel has issued a Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA) code for the company’s inFoods IBS test. This newly granted PLA code assigns a unique identifier to the test, allowing for the submission of claims to Medicare and private insurers once the code becomes effective on October 1, 2025. This represents a significant milestone in Biomerica’s commercialization strategy.
The issuance of a test-specific billing code streamlines the claims process and supports broader patient access to the inFoods IBS test. CEO Zack Irani stated that this is an important step toward enabling more patients to access the test through health insurance reimbursement, supporting the adoption of a personalized, non-drug approach to managing IBS symptoms. Chief Commercial Officer Scott Madel added that the PLA code strengthens their commercial strategy and positions them to accelerate insurance reimbursement efforts.
The inFoods IBS test is a first-of-its-kind diagnostic that identifies patient-specific food triggers for IBS symptoms, offering a targeted alternative to trial-and-error diets and symptom-masking medications. Clinical trial data published in *Gastroenterology* showed significantly greater symptom reduction for patients on an inFoods-guided diet. The PLA code improves transparency in reimbursement, positioning inFoods IBS as an important tool in the treatment and management of IBS and related gastrointestinal disorders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.